The draft regulation on mandatory joint clinical assessments got off to a poor start in the Council of the EU, if one is to judge from the comments of a number of health ministers at their meeting in Luxembourg on 22 June.
The draft regulation would put in place “joint clinical assessments” to determine the added value of the most innovative medicines and certain medical or in vitro devices to help member states come to decisions on pricing and reimbursement (see EUROPE 11951). The other...